Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint

20Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

Abstract

Background: Reduction in pulmonary exacerbations is an important efficacy endpoint for CF clinical studies. Powering exacerbation endpoints requires estimation of the future exacerbation incidence in CF study populations, but rates differ across the population. Methods: We have estimated exacerbation rates for Epidemiologic Study of CF subpopulations stratified by age, FEV 1% predicted, sex, weight-for-age percentile, respiratory signs and symptoms, and history of exacerbation and bacterial culture. Sample sizes required to attain 80% power to detect exacerbation reductions of 20% to 80% in 1:1 randomized studies of 3 to 12month duration were determined. Exacerbation treatments with "any" antibiotic (new oral quinolone, new inhaled antibiotic, or intravenous (IV) antibiotic) and with IV antibiotics were studied. Results: At all ages, decreased FEV 1, female sex, exacerbation history, and Pseudomonas aeruginosa culture history were associated with increased treatment for exacerbation. Conclusions: These data should assist investigators in the design of future CF exacerbation studies. © 2011 European Cystic Fibrosis Society.

Cite

CITATION STYLE

APA

VanDevanter, D. R., Yegin, A., Morgan, W. J., Millar, S. J., Pasta, D. J., & Konstan, M. W. (2011). Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. Journal of Cystic Fibrosis, 10(6), 453–459. https://doi.org/10.1016/j.jcf.2011.07.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free